The Global Oncolytic Virus Therapies Market Size, Share & Growth Analysis By Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), By Application (Solid Tumors, Melanoma), By End-Use (Hospitals, Specialty Clinics, Cancer Research Institute), And Regional Forecast, 2021-2027, This research & consulting report doles out information about the global Oncolytic Virus Therapies market. The forecast period of the market extends till 2027, while commencing in 2020. The report sheds light on various key insights & trends that have occupied center stage & drawn the attention of end-users. The Oncolytic Virus Therapies industry is witnessing impressive expansion at present, having logged double digit CAGRs in the past.
The global oncolytic virus therapies market size is expected to reach $619.7 Million in 2027 and register a compound annual growth rate (CAGR) of 26.1% during the forecast period.
The report alludes to the Oncolytic Virus Therapies market as a lucrative sector. This sector is slated to generate substantial revenues during forecast period 2021 to 2027. The analytical report highlights data & overview regarding the size, shares, & demand of Oncolytic Virus Therapies. Several other factors have had a positive or negative impact on the industry, all of which have been laid out in details.
request pdf sample copy
The said factors comprise drivers, novel prospects, hindrances, and other vital characteristics of the market. Investments by rivals into Oncolytic Virus Therapies products have catapulted the market into limelight & have stoked its demand, globally.
Few among other key aspects that find a mention; encompass the industry segments, predictions, & size and shares for 2021 to 2027. Besides these; the report narrows down on the innovative trends & technological developments, expansion strategies of key players, and regional statistics.
The manner in which nascent & local competitors stack up against prominent players, hogs the spotlight. Novel products & services, coupled with the monetary shares of eminent competitors and the SWOT analysis unveil the complexities of the global industry size.
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends from 2021 to 2027 in each of the sub segments. For the purpose of this study, Eternity Insights has segmented the global Oncolytic Virus Therapies market on the basis of virus type, application, end-use and region:
request pdf sample copy
Research methodology is an integral component of any kind of high-level market research. It entails evaluation by expert panels, research on secondary & primary levels, checks on quality, & testing on completion. Secondary research deeply focuses on the whys, whos, wheres, whens, & hows and caters to answering the strictly consumer-centric base of people.
Some other secondary research sources comprise governmental affiliations & blogs, business magazines, and industrial journals. Primary research includes face-to-face & telephonic interviews with industry experts. It is comparatively more detailed & lays stress on unprejudiced opinions about the products & services.
Primary research findings cement secondary research & help end-users & businesses get a better hang of various markets. It is a well-established fact, though, that research methodology is best implemented through the mixed execution of its aforementioned procedures.
What Does the Report Offer?
Other Vital Points That Are Covered
The market report also brings to light major opportunities and untapped geographies. It is more like a blend of customized research documents & conventional reports. Besides informing buyers about the pros & cons of direct and indirect sales channels, the analysis exhibits illustrations & graphical representations of industry growth and the innovative trends within the industry.
Table of Content
Chapter 1. Methodology & Sources
1.1. Market Definition
1.2. Research Scope
1.3. Methodology
1.4. Research Sources
1.4.1. Primary
1.4.2. Secondary
1.4.3. Paid Sources
1.5. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2020-2027
Chapter 3. Key Insights
Chapter 4. Oncolytic Virus Therapies Market Segmentation & Impact Analysis
4.1. Oncolytic Virus Therapies Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Rising number of clinical trials
4.2.2.2. Increasing adoption of inorganic growth strategies in the market
4.2.3. Market restraints analysis
4.2.3.1. High cost of therapy
4.3. Technological Insights
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.6. Competitive Metric Space Analysis
4.7. Price trend Analysis
4.8. Covid-19 Impact Analysis
Chapter 5. Oncolytic Virus Therapies Market By Virus Type Insights & Trends, Revenue (USD Million)
5.1. Virus Type Dynamics & Market Share, 2021 & 2027
5.1.1. Genetically Engineered Oncolytic Viruses
5.1.1.1. Herpes Simplex Virus
5.1.1.2. Adenovirus
5.1.1.3. Vaccinia Virus
5.1.2. Oncolytic Wild-Type Viruses
5.1.2.1. Reovirus
5.1.2.2. Newcastle Disease Virus
5.1.2.3. Vesicular Stomatitis Virus
Chapter 6. Oncolytic Virus Therapies Market By Application Insights & Trends Revenue (USD Million)
6.1. Application Dynamics & Market Share, 2021 & 2027
6.1.1. Solid Tumors
6.1.1.1. Breast Cancer
6.1.1.2. Prostate Cancer
6.1.1.3. Lung Cancer
6.1.1.4. Glioblastoma
6.1.1.5. Melanoma
6.1.2. Hematological Malignancies
6.1.2.1. Lymphoma
6.1.2.2. Leukemia
6.1.2.3. Myeloma
Chapter 7. Oncolytic Virus Therapies Market By End-use Insights & Trends Revenue (USD Million)
7.1. End-use Dynamics & Market Share, 2021 & 2027
7.1.1. Hospitals
7.1.2. Specialty Clinics
7.1.3. Cancer Research Institute
Chapter 8. Oncolytic Virus Therapies Market Regional Outlook
8.1. Oncolytic Virus Therapies Market Share By Region, 2021 & 2027
8.2. North America
8.2.1. Market By Virus Type, Market Estimates and Forecast, USD Billion
8.2.1.1. Genetically Engineered Oncolytic Viruses
8.2.1.1.1. Herpes Simplex Virus
8.2.1.1.2. Adenovirus
8.2.1.1.3. Vaccinia Virus
8.2.1.2. Oncolytic Wild-Type Viruses
8.2.1.2.1. Reovirus
8.2.1.2.2. Newcastle Disease Virus
8.2.1.2.3. Vesicular Stomatitis Virus
8.2.2. Market By Application, Market Estimates and Forecast, USD Billion
8.2.2.1. Solid Tumors
8.2.2.1.1. Breast Cancer
8.2.2.1.2. Prostate Cancer
8.2.2.1.3. Lung Cancer
8.2.2.1.4. Glioblastoma
8.2.2.2. Melanoma
8.2.2.2.1. Hematological Malignancies
8.2.2.2.2. Lymphoma
8.2.2.2.3. Leukemia
8.2.2.2.4. Myeloma
8.2.3. Market By End-use, Market Estimates and Forecast, USD Billion
8.2.3.1. Hospitals
8.2.3.2. Specialty Clinics
8.2.3.3. Cancer Research Institute
8.2.4. Market By Country, Market Estimates and Forecast, USD Billion
8.2.4.1. US
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. Europe
8.3.1. Market By Virus Type, Market Estimates and Forecast, USD Billion
8.3.1.1. Genetically Engineered Oncolytic Viruses
8.3.1.1.1. Herpes Simplex Virus
8.3.1.1.2. Adenovirus
8.3.1.1.3. Vaccinia Virus
8.3.1.2. Oncolytic Wild-Type Viruses
8.3.1.2.1. Reovirus
8.3.1.2.2. Newcastle Disease Virus
8.3.1.2.3. Vesicular Stomatitis Virus
8.3.2. Market By Application, Market Estimates and Forecast, USD Billion
8.3.2.1. Solid Tumors
8.3.2.1.1. Breast Cancer
8.3.2.1.2. Prostate Cancer
8.3.2.1.3. Lung Cancer
8.3.2.1.4. Glioblastoma
8.3.2.2. Melanoma
8.3.2.2.1. Hematological Malignancies
8.3.2.2.2. Lymphoma
8.3.2.2.3. Leukemia
8.3.2.2.4. Myeloma
8.3.3. Market By End-use, Market Estimates and Forecast, USD Billion
8.3.3.1. Hospitals
8.3.3.2. Specialty Clinics
8.3.3.3. Cancer Research Institute
8.3.4. Market By Country, Market Estimates and Forecast, USD Billion
8.3.4.1. Germany
8.3.4.2. U.K.
8.3.4.3. France
8.3.4.4. Spain
8.3.4.5. BENELUX
8.3.4.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Market By Virus Type, Market Estimates and Forecast, USD Billion
8.4.1.1. Genetically Engineered Oncolytic Viruses
8.4.1.1.1. Herpes Simplex Virus
8.4.1.1.2. Adenovirus
8.4.1.1.3. Vaccinia Virus
8.4.1.2. Oncolytic Wild-Type Viruses
8.4.1.2.1. Reovirus
8.4.1.2.2. Newcastle Disease Virus
8.4.1.2.3. Vesicular Stomatitis Virus
8.4.2. Market By Application, Market Estimates and Forecast, USD Billion
8.4.2.1. Solid Tumors
8.4.2.1.1. Breast Cancer
8.4.2.1.2. Prostate Cancer
8.4.2.1.3. Lung Cancer
8.4.2.1.4. Glioblastoma
8.4.2.2. Melanoma
8.4.2.2.1. Hematological Malignancies
8.4.2.2.2. Lymphoma
8.4.2.2.3. Leukemia
8.4.2.2.4. Myeloma
8.4.3. Market By End-use, Market Estimates and Forecast, USD Billion
8.4.3.1. Hospitals
8.4.3.2. Specialty Clinics
8.4.3.3. Cancer Research Institute
8.4.4. Market By Country, Market Estimates and Forecast, USD Billion
8.4.4.1. China
8.4.4.2. India
8.4.4.3. Japan
8.4.4.4. South Korea
8.4.4.5. Rest of APAC
8.5. Latin America
8.5.1. Market By Virus Type, Market Estimates and Forecast, USD Billion
8.5.1.1. Genetically Engineered Oncolytic Viruses
8.5.1.1.1. Herpes Simplex Virus
8.5.1.1.2. Adenovirus
8.5.1.1.3. Vaccinia Virus
8.5.1.2. Oncolytic Wild-Type Viruses
8.5.1.2.1. Reovirus
8.5.1.2.2. Newcastle Disease Virus
8.5.1.2.3. Vesicular Stomatitis Virus
8.5.2. Market By Application, Market Estimates and Forecast, USD Billion
8.5.2.1. Solid Tumors
8.5.2.1.1. Breast Cancer
8.5.2.1.2. Prostate Cancer
8.5.2.1.3. Lung Cancer
8.5.2.1.4. Glioblastoma
8.5.2.2. Melanoma
8.5.2.2.1. Hematological Malignancies
8.5.2.2.2. Lymphoma
8.5.2.2.3. Leukemia
8.5.2.2.4. Myeloma
8.5.3. Market By End-use, Market Estimates and Forecast, USD Billion
8.5.3.1. Hospitals
8.5.3.2. Specialty Clinics
8.5.3.3. Cancer Research Institute
8.5.4. Market By Country, Market Estimates and Forecast, USD Billion
8.5.4.1. Brazil
8.5.4.2. Rest of LATAM
8.6. Middle East and Africa
8.6.1. Market By Virus Type, Market Estimates and Forecast, USD Billion
8.6.1.1. Genetically Engineered Oncolytic Viruses
8.6.1.1.1. Herpes Simplex Virus
8.6.1.1.2. Adenovirus
8.6.1.1.3. Vaccinia Virus
8.6.1.2. Oncolytic Wild-Type Viruses
8.6.1.2.1. Reovirus
8.6.1.2.2. Newcastle Disease Virus
8.6.1.2.3. Vesicular Stomatitis Virus
8.6.2. Market By Application, Market Estimates and Forecast, USD Billion
8.6.2.1. Solid Tumors
8.6.2.1.1. Breast Cancer
8.6.2.1.2. Prostate Cancer
8.6.2.1.3. Lung Cancer
8.6.2.1.4. Glioblastoma
8.6.2.2. Melanoma
8.6.2.2.1. Hematological Malignancies
8.6.2.2.2. Lymphoma
8.6.2.2.3. Leukemia
8.6.2.2.4. Myeloma
8.6.3. Market By End-use, Market Estimates and Forecast, USD Billion
8.6.3.1. Hospitals
8.6.3.2. Specialty Clinics
8.6.3.3. Cancer Research Institute
8.6.4. Market By Country, Market Estimates and Forecast, USD Billion
8.6.4.1. Saudi Arabia
8.6.4.2. UAE
8.6.4.3. Israel
8.6.4.4. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Market Revenue Share By Manufacturers
9.2. Mergers & Acquisitions
9.3. Competitor’s Positioning
9.4. Strategy Benchmarking
9.5. Vendor Landscape
9.5.1. Raw Material Suppliers
9.5.1.1. North America
9.5.1.2. Europe
9.5.1.3. Asia Pacific
9.5.1.4. Middle East & Africa
9.5.1.5. Latin America
9.5.2. Distributors
9.5.2.1. North America
9.5.2.2. Europe
9.5.2.3. Asia Pacific
9.5.2.4. Middle East & Africa
9.5.2.5. Latin America
9.5.3. Others
Chapter 10. Company Profiles
10.1. Oncolytics Biotech, Inc.
10.1.1. Company Overview
10.1.2. Product & Service Offerings
10.1.3. Strategic Initiatives
10.1.4. Financials
10.1.5. Eternity Insights
10.2. Amgen Inc.
10.2.1. Company Overview
10.2.2. Product & Service Offerings
10.2.3. Strategic Initiatives
10.2.4. Financials
10.2.5. Eternity Insights
10.3. Sorrento Therapeutics, Inc.
10.3.1. Company Overview
10.3.2. Product & Service Offerings
10.3.3. Strategic Initiatives
10.3.4. Financials
10.3.5. Eternity Insights
10.4. Transgene SA
10.4.1. Company Overview
10.4.2. Product & Service Offerings
10.4.3. Strategic Initiatives
10.4.4. Financials
10.4.5. Eternity Insights
10.5. Daiichi Sankyo Company, Limited
10.5.1. Company Overview
10.5.2. Product & Service Offerings
10.5.3. Strategic Initiatives
10.5.4. Financials
10.5.5. Eternity Insights
10.6. Shanghai Sunway Biotech Co., Ltd.
10.6.1. Company Overview
10.6.2. Product & Service Offerings
10.6.3. Strategic Initiatives
10.6.4. Financials
10.6.5. Eternity Insights
10.7. Takara Bio Inc.
10.7.1. Company Overview
10.7.2. Product & Service Offerings
10.7.3. Strategic Initiatives
10.7.4. Financials
10.7.5. Eternity Insights
10.8. PsiOxus Therapeutics
10.8.1. Company Overview
10.8.2. Product & Service Offerings
10.8.3. Strategic Initiatives
10.8.4. Financials
10.8.5. Eternity Insights
10.9. SillaJen, Inc.
10.9.1. Company Overview
10.9.2. Product & Service Offerings
10.9.3. Strategic Initiatives
10.9.4. Financials
10.9.5. Eternity Insights
10.10. ViroCure
10.10.1. Company Overview
10.10.2. Product & Service Offerings
10.10.3. Strategic Initiatives
10.10.4. Financials
10.10.5. Eternity Insights
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
A faster and efficient way to cater to the needs with continuous iteration
Focus on Data Accuracy & Reliability
75+ Clients in Fortune 500
All your transactions are secured end-to-end, ensuring a satisfactory purchase
Ensure the best and affordable pricing
